Fusion Antibodies plc

New investors

Regulatory News

Updates

Company Presentations

Home

Fusion Deep Dive

Share Price

Shareholder Information

Advisers

Corporate Governance

Registrar & FAQs

AIM Rule 26

Board Profiles

Company Profile

Raleway

Whether you're a shareholder, investor, or just curious about what's happening at Fusion, we're thrilled to have you with us.

Fusion Antibodies (LSE: FAB) is a CRO that offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development.

We are a Belfast based, revenue generating CRO providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The Company's mission is to enable biopharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of global healthcare. Clients of the Company have a number of new drugs, in the development of which the Company has been involved.

The Company was established in 2001 as a spin out from Queen's University Belfast. It was initially a drug development business revising its operations in 2011 to focus on CRO work.

The Company provides a broad range of services in antibody discovery, development, characterisation, optimisation and production. These services include antigen design and expression, antibody discovery, purification and sequencing, antibody humanisation using the Company's proprietary CDRx™ platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced over 250 antibodies and successfully completed over 100 humanisation projects for its clients.

The Company has an international, blue-chip client base, which includes eight of the top ten global pharmaceutical companies by revenue. A significant amount of the Company's revenue is generated from follow on service requests from existing clients, providing good visibility of future earnings.

The Company's growth strategy is based on the expansion of its client base as well as the addition of new services including mammalian display to support AI/ML approaches to antibody generation as well as OptiMAL(R), our mammalian antibody library and OptiPhageTM which uses a similar library design rationale but the more commonly applied phage display format. This strategy uses the Company's novel and proven technology and expertise and targets expansion both in the UK market and internationally.

Our Investor Hub is the place for our shareholders and prospective investors to not only read our latest announcements and watch our latest videos, but also a place for them to interact with us directly. Have a question or a comment, send it through. We will endeavour to respond to your queries and remember, if sometimes we don't get back to you straightaway, it’s because we are busy executing our strategy and growing the business!

We are a Belfast-based contract research organisation (CRO) specialising in antibody engineering for therapeutic drug and diagnostic applications. Established in 2001 as a spin-out from Queen’s University Belfast, the company transitioned in 2011 to focus on providing antibody discovery, development, characterisation, and optimisation services. Using its proprietary 

, Fusion Antibodies offers antibody humanisation, stable cell line production, and sequencing, having successfully sequenced over 250 antibodies and completed more than 100 humanisation projects. With a blue-chip client base that includes eight of the world’s top ten pharmaceutical companies, the company generates significant recurring revenue from follow-on service requests.

Fusion Antibodies is committed to expanding its client base and service offering, incorporating 

mammalian display and AI/ML-driven antibody generation

 to advance discovery capabilities. Its proprietary 

 platform provide cutting-edge solutions tailored to modern biopharmaceutical needs. This growth strategy leverages the company’s expertise and technology to enhance its position in both the UK and global markets, supporting the rapid and cost-effective development of next-generation antibody-based therapies.

Get a deeper understanding of Fusion Antibodies and its vision for the future. In this exclusive series, CEO Adrian Kinkaid provides insight into the company’s strategy, market position, and the role it plays in advancing antibody discovery, giving investors the full picture of what makes Fusion unique.

Whether you're a shareholder, investor, or just curious about what's happening at Fusion Antibodies, we're thrilled to have you with us.

Our Investor Hub is the place for our shareholders and prospective investors to not only read our latest announcements and watch our latest videos, but also a place for them to interact with us directly.

Context on Fusion Antibodies